ู†ูˆุฑู…ูŠุชู† ูขูฅ

Land: Israel

Sprรฅk: arabisk

Kilde: Ministry of Health

Kjรธp det nรฅ

Aktiv ingrediens:

ATENOLOL 25 MG

Tilgjengelig fra:

ABIC LTD.

ATC-kode:

C07AB

Legemiddelform:

TABLETS

Administreringsrute:

PER OS

Produsert av:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Terapeutisk gruppe:

BETA BLOCKING AGENTS, SELECTIVE

Indikasjoner:

Management of angina pectoris and hypertension, including hypertension of renal origin. Late intervention after acute myocardial infarction.

Autorisasjon dato:

2012-01-01

Informasjon til brukeren

                                ื‘ืงืขืžื• ืชื•ืงื™ื“ื‘
ืจื•ื‘ืขืœ ืฉืจื“ื™ืชืฉ ืŸื›ืชื™ ,ื”ื™ืœื›ื‘ ืชื•ื™ืขื‘ืž ืœื‘ื•ืก
ืšื ื” ืื
.ืœื•ืคื™ื˜ื” ืชืคื•ืงืช ืšืฉืžื‘ ืชื•ืžื™ื•ืกืž ืชื•ืงื™ื“ื‘ ืื ื•ื ,ื”ืคื•ืจืชื” ืŸืž ืจืชื™ ืชื ืž ืชืœื˜ื  ืื
ืืคื•ืจืœ ื“ื™ืž ืชื•ื ืคืœ ืฉื™ ,ื”ืคื•ืจืชื” ืŸืž ื“ืœื™ ืขืœื‘
ืชื–ื™ืจื ืชื ืื™ื‘ื”ืœื• ืื™ืœื•ื— ืชื™ื‘ ืœืฉ ืŸื•ื™ืž ืจื“ื—ืœ
ื•ื
.ื”ืคื•ืจืชื”
,ืื“ื” ืฅื—ืœื‘ื• ืงืคื•ื“ื‘ ื”ื“ื™ืจื™ :ืจืชื™ ืŸื•ื ื™ืž ืœืฉ
ืชื•ืขืคื•ืช
ืจื•ืืœ ื”ื–ื—ื‘ ืฅื—ืœ ืชืฉื’ืจื” ,ืจื™ื“ืก ืืœ ื‘ืœ ื‘ืฆืง
,ื”ืžื™ืฉื  ื™ื™ืฉืงื• ื”ืžื™ืฉื ื” ื™ื›ืจื“ ื™ืจื™ืจืฉ
ืชื•ืฆื•ื•ื›ืชื”
.ืŸื•ืคืœื™ืข ืื™ืชื™ืขืœ ื•ื ,ืืœื”ื• ื‘ืœื” ื“ื•ืงืคืชื‘
ื”ืขื™ื’ืค
ื”ืคื•ืจืชื” ืชื ืœื•ื˜ื™ืœ ืชื—ื›ืฉ ืื
ืŸื™ื ,ืฉื•ืจื“ื” ืŸืžื–ื‘ ื•ื– ื”ืคื•ืจืช ืœื•ื˜ื™ืœ ืชื—ื›ืฉ ืื
ืŸืžื–ื‘ ื”ืื‘ื” ื”ื ืžื” ืชื ื—ืง .ื”ืœื•ืคื› ื”ื ืž ืœื•ื˜ื™ืœ
.ืืคื•ืจื‘ ืฅืขื•ื•ื™ื”ื• ืœื™ื’ืจื”
ืšื™ืœืข ,ืชืœื˜ื ื• ื”ื“ื™ืžื‘ !ื“ื—ื™ื‘ ืชื•ื ืž ื™ืชืฉ ืœื•ื˜ื™ืœ
ืŸื™ื
.ื—ืงื•ืจื‘ ื•ื ืืคื•ืจื‘ ืฅืขื•ื•ื™ื”ืœ
.ืืคื•ืจื” ื™ื“ื™-ืœืข ืฅืœืžื•ื”ืฉ ื™ืคื› ืœื•ืคื™ื˜ื‘ ื“ื™ืžืชื”ืœ
ืฉื™
ืงื™ืกืคื”ืœ ืŸื™ื ,ืšืชื•ืื™ืจื‘ ื‘ืฆืžื‘ ืจื•ืคื™ืฉ ืœื— ืื ืื’
ืืข ื”ืžื™ื“ืงืž ืชื•ืฆืขื™ื™ืชื” ืืœืœ ื”ืคื•ืจืชื‘ ืœื•ืคื™ื˜ื”
.ื—ืงื•ืจื” ื•ื ืืคื•ืจื”
ื”ืคื•ืจืชื” ืชืœื™ื˜ื  ืชื ืงื™ืกืคืž ื”ืชื ืื
.ืืคื•ืจื‘ ืชืฆืขื•ื  ืืจื˜ื‘ ื•ื– ื”ืคื•ืจืช ืœื•ื˜ื™ืœ ืงื™ืกืคืช
ืœื
ื”ื’ืจื“ื”ื‘ ืขืฆื•ื‘ืช ืœื•ืคื™ื˜ื” ืชืงืกืคื” ,ืื™ืžื™ื•ืกืž
ืื™ืจืงืžื‘
.ืจื•ื˜ื™ื  ืขื•ืฆื™ื‘ ื™ื“ื› ืšื•ืช ืื™ืžื™ 7-14 ืšืจื•ืืœ
?ืœื•ืคื™ื˜ื” ืชื—ืœืฆื”ืœ ืขื™ื™ืกืœ ืœื›ื•ืช ื“ืฆื™ื›
ื”ื ืžื”ื• ืชื™ื•ื•ืชื” ืงื•ื“ื‘ !ืšืฉื•ื—ื‘ ืชื•ืคื•ืจืช ืœื•ื˜ื™ืœ
ืŸื™ื
ืื™ื™ืคืงืฉืž ื‘ื›ืจื” .ื”ืคื•ืจืช ืœื˜ื•ื  ืšื ื”ืฉ ืืขืค ืœื›ื‘
.ืื”ืœ ืงื•ืงื– ืšื ื” ืื
,ื”ืคื•ืจืชื‘ ืฉื•ืžื™ืฉืœ ืขื’ื•ื ื‘ ืชื•ืคืกื•ื  ืชื•ืœืืฉ ืšืœ
ืฉื™ ืื
.ื—ืงื•ืจื‘ ื•ื ืืคื•ืจื‘ ืฅืขื•ื•ื™ื”
ื™ืื•ื•ืœ ืชื•ืขืคื•ืช .4
ืื•ืจื’ืœ ืœื•ืœืข ืŸื˜ื™ืžืจื•ื ื‘ ืฉื•ืžื™ืฉื” ,ื”ืคื•ืจืช ืœื›ื‘
ื•ืžื›
ืœื”ื‘ื™ืช ืœื .ืื™ืฉืžืชืฉืžื”ืž ืงืœื—ื‘ ื™ืื•ื•ืœ ืชื•ืขืคื•ืชืœ
ืœื•ื‘ืกืช ืืœื• 
                                
                                Les hele dokumentet
                                
                            

Dokumenter pรฅ andre sprรฅk

Informasjon til brukeren Informasjon til brukeren engelsk 15-12-2016
Preparatomtale Preparatomtale engelsk 25-06-2017
Offentlig vurderingsrapport Offentlig vurderingsrapport engelsk 17-08-2016
Informasjon til brukeren Informasjon til brukeren hebraisk 15-12-2016

Sรธk varsler relatert til dette produktet